In this virtual tumor board, the participants will hear a case-based discussion that will include:

• Molecular profiling of tumors and how the emerging role of immunotherapy can impact the management of soft tissue sarcoma patients.
• The relationship of gastrointestinal stromal tumor (GIST) mutational status with systemic treatment selection.
• The role of anaplastic lymphoma kinase (ALK) inhibitors as a treatment option for ALK positive inflammatory myofibroblastic tumor (IMT).
• Situations where next-generation sequencing (NGS) might identify potential novel treatment targets.

Indications for immunotherapy in select soft tissue sarcoma patients.